Exploiting fucoxanthin mono-carrier nanoparticles to modulate digestion and metabolic regulation in an obesity model

Fucoxanthin (FX), a natural compound derived from marine algae, and FX-based nanoparticles (FZ) were investigated for their potential in regulating glucose and lipid metabolism. Gavage interventions with FX, FZ, and zein hydrolysate (ZH) were administered to obese mice, resulting in significant outcomes. These interventions led to variations in growth rates, reduced blood glucose levels, improved lipid profiles, and ameliorated liver pathology. Our mRNA expression analysis revealed modulation of key genes involved in glucose metabolism. Gut analysis, including short-chain fatty acid detection and 16S rRNA gene sequencing, provided insights into gut microbiota modulation. Notably, differences observed in vivo between FX and FZ were attributed to their distinct release rates during in vitro digestion in the stomach and intestine. This comprehensive study validates our methods, modeling, and metabolic parameter determination, reinforcing the significance of our results. In conclusion, our findings highlight the promising potential of FX-encapsulated interventions in modulating metabolic pathways. Furthermore, they emphasize the crucial role of gut microbiota dynamics in the strategic mitigation of disorders associated with obesity.